- Broad method of use patent protection for COM902, a potential
best-in-class reduced Fc, clinical stage, anti-TIGIT antibody,
in triple combination with any anti-PD-1 antibody and any
anti-PVRIG antibody for the treatment of cancer
- Further strengthens Compugen's IP portfolio across DNAM-1 axis
checkpoint inhibitors
HOLON, Israel, Nov. 27,
2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)
(TASE: CGEN) a clinical-stage cancer immunotherapy company and a
pioneer in computational target discovery, today announced that the
United States Patent and Trademark Office (USPTO) has granted the
Company a new patent covering method of use for COM902, the
Company's potential best-in-class reduced Fc, clinical stage
antibody targeting TIGIT, and additional TIGIT backup antibodies in
triple combination with any anti-PD-1 antibody and any anti-PVRIG
antibody for the treatment of cancer.
U.S. Patent No. 12152084 titled "Triple combination
antibody therapies" augments patents previously issued to Compugen
by expanding and protecting the use of COM902 and backup antibodies
for treating cancer patients, to include the triplet combination of
COM902 with any anti-PD-1 antibody and any anti-PVRIG antibody.
"Protecting COM902 in combination with any anti-PVRIG antibody
and any anti-PD-1 antibody is an important part of our strategy to
bring innovative treatments to patients and value to our
shareholders," said Anat
Cohen-Dayag, Ph.D., President, and Chief Executive Officer
of Compugen. "Recent developments in the TIGIT landscape point to
the potential advantage of anti-TIGITs without an active Fc binder
such as COM902. Our data also suggest that blocking TIGIT may be
insufficient to provide optimal anti-tumor activity in certain
tumor types, including those non-responsive to PD-1 inhibition, and
blocking PD-1 and PVRIG in parallel may be needed to provide
optimal benefit. In our next study we plan to evaluate our
potential first-in-class, anti-PVRIG antibody, COM701, in an
adaptive platform trial designed to first establish its monotherapy
benefit and as a potential backbone for future drug combinations,
including with COM902, anti-PD-1 and others."
U.S. Patent No. 12152084 is expected to expire no earlier
than August 2037 in the United
States.
About Compugen
Compugen is a
clinical-stage therapeutic discovery and development company
utilizing its broadly applicable predictive computational discovery
platform (Unigen™) to identify new drug targets and
biological pathways for developing cancer immunotherapies. Compugen
has two proprietary product candidates in Phase 1 development:
COM701, a potential first-in-class anti-PVRIG antibody and
COM902, a potential best-in-class reduced Fc antibody
targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a
PD-1/TIGIT bispecific antibody where the TIGIT component is derived
from Compugen's clinical stage anti-TIGIT antibody, COM902, is in
Phase 3 development by AstraZeneca through a license agreement for
the development of bispecific and multispecific antibodies. In
addition, the Company's therapeutic pipeline of
early-stage immuno-oncology programs consists of programs
aiming to address various mechanisms of immune resistance, of which
the most advanced program, COM503, a potential first-in-class, high
affinity anti-IL-18 binding protein antibody, which has been
granted IND clearance from the FDA, is licensed to Gilead.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN.
Forward-Looking Statement
This press release contains
"forward-looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended,
and the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements are based on
the current beliefs, expectations, and assumptions of Compugen.
Forward-looking statements can be identified using terminology such
as "will," "may," "expects," "anticipates," "believes,"
"potential," "plan," "goal," "estimate," "likely," "should,"
"confident," and "intends," and similar expressions that are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements include, but are not limited to,
statement regarding the potential advantage of anti-TIGITs without
an active Fc binder, such as COM902; statements indicating that
blocking TIGIT may be insufficient to provide optimal anti-tumor
activity in certain tumor types, including those non-responsive to
PD-1 inhibition; statements to the effect that blocking PD-1 and
PVRIG in parallel may be needed to provide optimal benefit; and
statements regarding our next study. These forward-looking
statements involve known and unknown risks and uncertainties that
may cause the actual results, performance, or achievements of
Compugen to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Among these risks: Compugen's business
model is substantially dependent on entering into collaboration
agreements with third parties and Compugen may not be successful in
generating adequate revenues or commercializing aspects of its
business model; Compugen may not be able to advance its internal
clinical stage programs through clinical development or
manufacturing or successfully partner or commercialize them, or
obtain marketing approval, either alone or with a collaborator, or
may experience significant delays in doing so; clinical development
involves a lengthy and expensive process, with an uncertain outcome
and Compugen may encounter substantial delays or even an inability
to begin clinical trials for any specific product or may not be
able to conduct or complete its trials on the timelines it expects;
Compugen has limited experience in the development of therapeutic
product candidates, and it may be unable to implement its business
strategy; the general market, political and economic conditions in
the countries in which Compugen operates, including Israel; and the effect of the evolving nature
of the recent war in in Israel.
These risks and other risks are more fully discussed in the "Risk
Factors" section of Compugen's most recent Annual Report on Form
20-F as filed with the Securities and Exchange Commission (SEC) as
well as other documents that may be subsequently filed by Compugen
from time to time with the SEC. In addition, any forward-looking
statements represent Compugen's views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Compugen does not assume any obligation to
update any forward-looking statements unless required by law.
Company contact:
Yvonne
Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate
Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-expands-its-intellectual-property-portfolio-with-new-us-patent-covering-triple-combination-use-of-com902-reduced-fc-anti-tigit-with-anti-pd-1-and-anti-pvrig-antibodies-302317405.html
SOURCE Compugen Ltd.
